Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo

Circulation

Volumn 109, Issue 21, 2004, Pages 2554-2559

  Schäfers, Michael ^a,b,d   Riemann, Burkhard ^a   Kopka, Klaus ^a   Breyholz, Hans Jörg ^a   Wagner, Stefan ^a   Schäfers, Klaus P ^a   Law, Marilyn P ^a   Schober, Otmar ^a   Levkau, Bodo ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d Dept of Nucl Med Exp Nucl Med ^*  (Germany)

Author keywords

Atherosclerosis; Imaging; Metalloproteinases; Nuclear medicine

Indexed keywords

CGS 27023A; IODINE 123; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; RADIOLIGAND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; CANCER; CAROTID ARTERY LIGATION; CHOLESTEROL DIET; CONTROLLED STUDY; DIAGNOSTIC TEST; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; IMAGING; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCINTIGRAPHY;

ANIMALS; APOLIPOPROTEINS E; AUTORADIOGRAPHY; CAROTID ARTERY, COMMON; DIET, ATHEROGENIC; FEASIBILITY STUDIES; HYDROXAMIC ACIDS; IODINE RADIOISOTOPES; LIGATION; MACROPHAGES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEASE INHIBITORS; PYRAZINES; RADIOPHARMACEUTICALS; SULFONAMIDES;

EID: 2642575025     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000129088.49276.83     Document Type: Article

References (20)

1. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002;3:207-214.
2. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251-262.
3. World Health Report 2002. Reducing risks, promoting healthy life. World Health Organization; 2002.
4. Blankenberg FG, Strauss HW. Nuclear medicine applications in molecular imaging. J Magn Reson Imaging. 2002;16:352-361.
5. Nagase H, Brew K. Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics. Arthritis Res. 2002;4:S51-S61.
6. MacPherson LJ, Bayburt EK, Capparelli MP, et al. Discovery of CGS 27023A, a nonpeptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem. 2002;40:2525-2532.
7. 125I]iodophenacyl)-17-demethoxygeldanamycin: an ansamycin for photoaffinity labelling. J Labelled Cpd Radiopharm. 1994;34:529-535.
8. Edgar KJ, Falling SN. An efficient and selective method for the preparation of iodophenols. J Org Chem. 1990;55:5287-5291.
9. Kopka K, Breyholz HJ, Wagner S, et al. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl Med Biol. 2004;31:257-267.
10. Ivan E, Khatri JJ, Johnson C, et al. Expansive arterial remodeling is associated with increased neointimal macrophage foam cell content: the murine model of macrophage-rich carotid artery lesions. Circulation. 2002;105:2686-2691.
11. Huang W, Meng Q, Suzuki K, et al. Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases. J Biol Chem. 1997;272:22086-22091.
12. Ong AC, Newby LJ, Dashwood MR. Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease. Nephron Exp Nephrol. 2003;93:e80-e86.
13. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178-193.
14. Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002;91:852-859.
15. 11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol. 2002;29:761-770.
16. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001;7:743-748.
17. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002;8:1257-1262.
18. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92:1565-1569.
19. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
20. Johnson JL, Jackson CL. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis. 2001;154:399-406.